Cancer therapy in the necroptosis era
View/ Open
Author
Su, Z
Yang, Z
Xie, L
DeWitt, J P
Chen, Y
Published Version
https://doi.org/10.1038/cdd.2016.8Metadata
Show full item recordCitation
Su, Z, Z Yang, L Xie, J P DeWitt, and Y Chen. 2016. “Cancer therapy in the necroptosis era.” Cell Death and Differentiation 23 (5): 748-756. doi:10.1038/cdd.2016.8. http://dx.doi.org/10.1038/cdd.2016.8.Abstract
Necroptosis is a caspase-independent form of regulated cell death executed by the receptor-interacting protein kinase 1 (RIP1), RIP3, and mixed lineage kinase domain-like protein (MLKL). Recently, necroptosis-based cancer therapy has been proposed to be a novel strategy for antitumor treatment. However, a big controversy exists on whether this type of therapy is feasible or just a conceptual model. Proponents believe that because necroptosis and apoptosis use distinct molecular pathways, triggering necroptosis could be an alternative way to eradicate apoptosis-resistant cancer cells. This hypothesis has been preliminarily validated by recent studies. However, some skeptics doubt this strategy because of the intrinsic or acquired defects of necroptotic machinery observed in many cancer cells. Moreover, two other concerns are whether or not necroptosis inducers are selective in killing cancer cells without disturbing the normal cells and whether it will lead to inflammatory diseases. In this review, we summarize current studies surrounding this controversy on necroptosis-based antitumor research and discuss the advantages, potential issues, and countermeasures of this novel therapy.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832112/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:27320203
Collections
- HMS Scholarly Articles [17917]
Contact administrator regarding this item (to report mistakes or request changes)